Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 24;27(4):717-726.
doi: 10.5935/1518-0557.20230029.

Using GnRH agonists in combination with hCG in antagonist ART cycles: A SCOPING Review of recent evidences

Neeta Singh  1 , Aryan Kashyap  1 , Garima Patel  1 , Richa Vatsa  1
Affiliations
Review

Using GnRH agonists in combination with hCG in antagonist ART cycles: A SCOPING Review of recent evidences

Neeta Singh et al. JBRA Assist Reprod. .

Abstract

Assisted Reproductive technology encompasses all techniques involving ovarian stimulation to produce high-quality oocytes and manipulation of both oocytes and sperm in vitro to produce embryos for the purpose of reproduction. The final maturation of oocytes induced by a "trigger" is a crucial step with the potential to affect in vitro fertilization outcomes. Human chorionic gonadotropin has traditionally been used as a substitute for luteinizing hormone to induce final oocyte maturation and meiosis. However, this practice may cause a potentially fatal iatrogenic complication known as ovarian hyperstimulation syndrome, which can cause significant morbidity and, in rare cases, death in otherwise healthy women. Thus, gonadotropin releasing hormone agonists have been promoted as a safer alternative for inducing oocyte maturation, albeit at the expense of luteal phase defect. Since then, various combinations of gonadotropin releasing hormone agonists and human chorionic gonadotropin have been tried. This scoping review evaluates these trigger combinations in various types of responders.

Keywords: gonadotropin releasing hormone agonist; human chorionic gonadotropin; oocyte maturation.; trigger.

PubMed Disclaimer

References

    1. Ali SS, Elsenosy E, Sayed GH, Farghaly TA, Youssef AA, Badran E, Abbas AM, Abdelaleem AA. Dual trigger using recombinant HCG and gonadotropin-releasing hormone agonist improve oocyte maturity and embryo grading for normal responders in GnRH antagonist cycles: Randomized controlled trial. J Gynecol Obstet Hum Reprod. 2020;49:101728. doi: 10.1016/j.jogoh.2020.101728. - DOI - PubMed
    1. Alleyassin A, Ghasemi M, Aghahosseini M, Safdarian L, Sarvi F, Hosseinimousa S, Najafian A, Esmailzadeh A. Final oocyte maturation with a dual trigger compared to human chorionic gonadotropin trigger in antagonist co-treated cycles: A randomized clinical trial. Middle East Fertil Soc J. 2018;23:199–204. doi: 10.1016/j.mefs.2018.01.001. - DOI
    1. Beck-Fruchter R, Weiss A, Lavee M, Geslevich Y, Shalev E. Empty follicle syndrome: successful treatment in a recurrent case and review of the literature. Hum Reprod. 2012;27:1357–1367. doi: 10.1093/humrep/des037. - DOI - PubMed
    1. Casarini L, Lispi M, Longobardi S, Milosa F, La Marca A, Tagliasacchi D, Pignatti E, Simoni M. LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling. PLoS One. 2012;7:e46682. doi: 10.1371/journal.pone.0046682. - DOI - PMC - PubMed
    1. Castillo JC, Humaidan P, Bernabéu R. Pharmaceutical options for triggering of final oocyte maturation in ART. Biomed Res Int. 2014;2014:580171. doi: 10.1155/2014/580171. - DOI - PMC - PubMed